(Precision Vaccinations)
Novavax, Inc. announced yesterday that its protein-based COVID-19 vaccine had been granted full Marketing Authorization (MA) by the European Commission in the European Union (EU).
The Nuvaxovid™ (NVX-CoV2373) vaccine is now fully authorized for use in the EU as a primary series in individuals aged 12 and older.
And as a booster dose in adults aged 18 and older to prevent COVID-19.
During the diminishing pandemic, Novavax’s COVID vaccine has been authorized for use in more than 40 markets worldwide.
“This Marketing Authorization establishes the foundation for all future regulatory approvals for updated versions of our COVID vaccine, a necessity to ensure we can quickly get our vaccine to individuals in the EU,” said John C. Jacobs, President and Chief Executive Officer, Novavax, in a press release on July 6, 2023.
“In addition to the EU, we are preparing to file for full approval in the U.S. and other markets and are committed to ensuring protein-based options are available worldwide.”
“Vaccine choice remains an integral part of public health measures.”
The U.S. Food and Drug Administration has not yet approved the trade name Nuvaxovid™, nor has it been approved or licensed.
However, as of July 7, 2023, it has been authorized for emergency use under an Emergency Use Authorization for various people. In Europe, over ten COVID-19 vaccines are available.
Zalika is always online with new technologies and trends in the pharmaceutical industry in Brazil and around the world.
